Lineage Cell Therapeutics has not been the subject of major, systemic corporate litigation or catastrophic class-action lawsuits threatening its core business operations. Like many publicly traded biotechnology companies, it operates under strict regulatory frameworks and continuous disclosure obligations, routinely resolving normal administrative or corporate governance matters without material legal liability impacts.